ArticlePLoS biology2016
Structure, Regulation, and Inhibition of the Quorum-Sensing Signal Integrator LuxO.
Article in PLoS biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 41 citations in OpenAlex.
- Prophage-Derived Molecules as Anti-Antibiotics (Basel, Switzerland) · 2026Review
- Quorum-quenching enzymes as next-generation antibiofilm therapeutics: mechanisms, applications, and future perspectives.World journal of microbiology & biotechnology · 2026Review
- Article
- Deployment of amBio · 2025Article
- Molecular structural arrangement in quorum sensing and bacterial metabolic production.World journal of microbiology & biotechnology · 2025Review
- ARR1 and AHP interactions in the multi-step phosphorelay system.Frontiers in plant science · 2025Article
- Characterization of tryptanthrin as an antibacterial reagent inhibiting Vibrio splendidus.Applied microbiology and biotechnology · 2024Article
- Deployment of abioRxiv : the preprint server for biology · 2024Article
- Cholera Outbreaks in Zimbabwe: An In-Depth Analysis of Drivers, Constraints and Reimagining the Use of Medicinal Plants.Journal of tropical medicine · 2024Review
- Identification of critical amino acids in the DNA binding domain of LuxO: Lessons from a constitutive active LuxO.PloS one · 2024Article
- CombinedACS omega · 2023Article
- Natural silencing of quorum-sensing activity protects Vibrio parahaemolyticus from lysis by an autoinducer-detecting phage.PLoS genetics · 2023Article
- Natural Silencing of Quorum-Sensing Activity ProtectsbioRxiv : the preprint server for biology · 2023Article
- A Geneticist Transcribing the Chemical Language of Bacteria.Israel journal of chemistry · 2023Article
- Two enhancer binding proteins activate σeLife · 2023Article
- Small regulatory RNAs inmicroLife · 2023Review
- Design of novel anti-quorum sensing peptides targeting LuxO to combatIn silico pharmacology · 2023Article
- Article
- LuxT controls specific quorum-sensing-regulated behaviors in Vibrionaceae spp. via repression of qrr1, encoding a small regulatory RNA.PLoS genetics · 2021Article
- Cross-kingdom inhibition of bacterial virulence and communication by probiotic yeast metabolites.Microbiome · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
In a process called quorum sensing, bacteria communicate with chemical signal molecules called autoinducers to control collective behaviors. In pathogenic vibrios, including Vibrio cholerae, the accumulation of autoinducers triggers repression of genes responsible for virulence factor production and biofilm formation. The vibrio autoinducer molecules bind to transmembrane receptors of the two-component histidine sensor kinase family. Autoinducer binding inactivates the receptors' kinase activities, leading to dephosphorylation and inhibition of the downstream response regulator LuxO. Here, we report the X-ray structure of LuxO in its unphosphorylated, autoinhibited state. Our structure reveals that LuxO, a bacterial enhancer-binding protein of the AAA+ ATPase superfamily, is inhibited by an unprecedented mechanism in which a linker that connects the catalytic and regulatory receiver domains occupies the ATPase active site. The conformational change that accompanies receiver domain phosphorylation likely disrupts this interaction, providing a mechanistic rationale for LuxO activation. We also determined the crystal structure of the LuxO catalytic domain bound to a broad-spectrum inhibitor. The inhibitor binds in the ATPase active site and recapitulates elements of the natural regulatory mechanism. Remarkably, a single inhibitor molecule may be capable of inhibiting an entire LuxO oligomer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.